Atavistik Bio Inc. has nominated an orally bioavailable selective allosteric AKT1 E17K inhibitor, ATV-1601, as a development candidate for AKT1 E17K-driven cancers.
Molecure SA has signed an exclusive licensing agreement with Ocean Biomedical Inc. for the development and commercialization of a selective YKL-40 inhibitor program, including the lead molecule OAT-3912.
In a recent presentation, researchers from the Medical University of Lodz have aimed to investigate the therapeutic potential of simultaneously targeting axin and cannabinoid receptors (CBs) with KYA-1797K and WIN-55212-2 in colorectal cancer (CRC) cell lines SW480 and Caco-2.
In recent years, immune checkpoint inhibitors have had great success in the treatment of advanced cancers, but often, they are only effective in a minority of patients. Researchers from Weill Cornell Medicine have discovered that the activation of the pentose phosphate pathway (PPP) in combination with standard immune checkpoint inhibitors resulted in enhanced antitumor efficacy both in vitro and in vivo.
Virus is associated with sickness, but oncolytic virus therapies, which harness viruses to attack and kill cancer cells, may soon change the standard of treatment for cancer, including those long deemed uncurable like malignant glioma.
Ligachem Bioscience Inc., of Daejeon, South Korea, and Osaka, Japan-based Ono Pharmaceutical Co. Ltd. agreed to two antibody-drug conjugate (ADC) deals that could reach $700 million (₩943.5 billion) combined.
Breast cancer cells, when disseminated to other secondary organs such as the lungs, may stay in a dormant state for years, even decades. But the mechanisms that limit their expansion are not well understood. This is what researchers call a dormant mesenchymal-like phenotype before metastasis to the lungs. Now, scientists have shown in a study published Oct. 7, 2024, in Cell, that the limiting of disseminated breast cancer cells (DCCs) to metastasize in the lungs is due to alveolar macrophages, which activate signals that make DCCs stay dormant.
Shanghai Helioson Pharmaceutical Co. Ltd. has identified molecular glue degraders acting as DNA-binding protein Ikaros (IKZF1) and/or zinc finger protein Aiolos (IKZF3) degradation inducers reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
RSS
